Lupin receives U.S. approval for another drug
Thursday, 31 July 2008, 07:00 Hrs
New Delhi: Drug major Lupin announced Thursday that its U.S. subsidiary, Lupin Pharmaceuticals (LPI) has received final approval for the company's Abbreviated New Drug Application (ANDA) for divalproex sodium delayed-release tablets from the U.S. Food and Drug Administration (FDA). The tablets will be available in 125 mg, 250 mg and 500 mg variants. Commercial shipments have commenced, the company said in a regulatory statement Thursday. With the approval of this tablet the cumulative ANDA approvals of the company stand at 31 with 34 pending approval from the FDA.